- Home
- FRST vs DSGN Comparison
FRST vs DSGN Comparison
Compare FRST & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRST
- DSGN
- Stock Information
- Founded
- FRST 2004
- DSGN 2017
- Country
- FRST United States
- DSGN United States
- Employees
- FRST N/A
- DSGN N/A
- Industry
- FRST Major Banks
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- FRST Finance
- DSGN Health Care
- Exchange
- FRST Nasdaq
- DSGN Nasdaq
- Market Cap
- FRST 220.5M
- DSGN 208.9M
- IPO Year
- FRST 2006
- DSGN 2021
- Fundamental
- Price
- FRST $11.10
- DSGN $3.53
- Analyst Decision
- FRST Buy
- DSGN Hold
- Analyst Count
- FRST 1
- DSGN 1
- Target Price
- FRST $420.00
- DSGN $4.00
- AVG Volume (30 Days)
- FRST 80.9K
- DSGN 86.3K
- Earning Date
- FRST 07-24-2025
- DSGN 08-04-2025
- Dividend Yield
- FRST 3.69%
- DSGN N/A
- EPS Growth
- FRST N/A
- DSGN N/A
- EPS
- FRST 0.16
- DSGN N/A
- Revenue
- FRST $125,133,000.00
- DSGN N/A
- Revenue This Year
- FRST $21.33
- DSGN N/A
- Revenue Next Year
- FRST $12.77
- DSGN N/A
- P/E Ratio
- FRST $67.58
- DSGN N/A
- Revenue Growth
- FRST 22.34
- DSGN N/A
- 52 Week Low
- FRST $7.59
- DSGN $2.60
- 52 Week High
- FRST $13.52
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- FRST 71.80
- DSGN 42.03
- Support Level
- FRST $10.40
- DSGN $3.33
- Resistance Level
- FRST $10.92
- DSGN $4.21
- Average True Range (ATR)
- FRST 0.21
- DSGN 0.22
- MACD
- FRST 0.08
- DSGN -0.05
- Stochastic Oscillator
- FRST 92.06
- DSGN 22.29
About FRST Primis Financial Corp.
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. Primis Bank offers a broad range of deposit products, including checking (NOW), savings, money market accounts, and certificates of deposit.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.